Related Experiment Video
Updated: May 21, 2026
08:35
Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
Published on: January 4, 2012
Targeting eNOS in pancreatic cancer
Benjamin L Lampson1, S Disean Kendall, Brooke B Ancrile
1Departments of Pharmacology & Cancer Biology, Duke University Medical Center, Durham, North Carolina, USA.
Cancer Research
|June 29, 2012
Summary
Targeting endothelial nitric oxide synthase (eNOS) shows promise for pancreatic cancer treatment. Inhibiting eNOS with l-NAME slowed tumor growth and extended lifespan in preclinical models, suggesting repurposing for PDAC therapy.
Area of Science:
- Oncology
- Biochemistry
- Molecular Biology
Background:
- Pancreatic ductal adenocarcinoma (PDAC) has high mortality with limited therapeutic advancements.
- Endothelial nitric oxide synthase (eNOS) activation is increasingly implicated in PDAC development and progression.
Purpose of the Study:
- To investigate the therapeutic potential of targeting eNOS in PDAC.
- To evaluate the efficacy of eNOS inhibition in preclinical models of pancreatic cancer.
Main Methods:
- Utilized genetically engineered mouse models and human xenograft models of PDAC.
- Assessed the impact of genetic eNOS deficiency and pharmacological inhibition with l-NAME.
- Examined effects on preinvasive lesions, tumor growth, and lifespan.
Main Results:
- Genetic eNOS deficiency limited preinvasive lesion development and extended survival in advanced PDAC mouse models.
- Oral administration of l-NAME, a clinically evaluated NOS inhibitor, replicated these beneficial effects.
- l-NAME treatment inhibited tumor growth in various oncogenic KRas-driven tumor models and human pancreatic cancer xenografts.
Conclusions:
- Findings provide preclinical evidence supporting the repurposing of l-NAME for PDAC treatment.
- eNOS inhibition represents a potential therapeutic strategy for PDAC and other KRas-driven cancers.
